FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220807744> ?p ?o ?g. }

• W4220807744 endingPage "33" @default.
• W4220807744 startingPage "P2" @default.
• W4220807744 abstract "Abstract Background: Many HER2-directed antibody-drug conjugates (ADCs) in early development employ trastuzumab linked to tubulin binding agents as the cytotoxic drug. DHES0815A is an ADC consisting of a THIOMABTM humanized IgG1 anti-HER2 monoclonal antibody (hu7C2), which binds domain 1 of the HER2 ECD, conjugated via a disulfide linker to PBD-monoamide (MA), a DNA mono-alkylating agent. The reduced potency of the PBD-MA payload compared to PBD dimers and the stability of the conjugation site and linker were designed to improve tolerability, whereas the binding of hu7C2 to a HER2 epitope distinct from trastuzumab and pertuzumab allows combination with existing HER2 therapies. . Methods: Modifications at one imine in the PBD (pyrrolobenzodiazepine) dimer produced mono-alkylating PBDs that were assessed for DNA binding, permeability and cell potency. Each modified PBD was conjugated to hu7C2 LC K149C via a disulfide linker and assessed in HER2-positive models in vitro and in vivo. Safety studies were performed in female and male cynomolgus monkey treated every 3 weeks X 5, with a 7-week follow-up. Assessments included hematology, clinical chemistry, anti-drug antibody, standard clinical, neurological and ophthalmic exams and histopathology. Results: Our goal was design of a reduced potency PBD dimer ADC to achieve dosing in the linear PK range for optimal exposure, efficacy and safety. PBD dimers contain 2 reactive imines that bis-alkylate and crosslink DNA. Mono-alkylating PBD dimers were assessed in DNA binding, potency and permeability assays to select the optimal mono-alkylator, PBD-MA, for further investigation. hu7C2-disulfide-PBD-MA, or DHES0815A, was potent across HER2-positive breast and gastric cancer models in vitro and in vivo, with little effect on HER2-negative tumors or normal primary cells in vitro. DHES0815A was more potent than T-DM1 in HER2-positive and HER2-low breast and gastric cancer PDX models and demonstrated combination activity with standard of care agents T-DM1 or docetaxel. Mechanistically, treatment of HER2-positive cells with DHES0815A resulted in late S-phase cell cycle arrest; induction of DNA damage markers γH2AX, phospho-p53, phospho-CHK2, induction of apoptosis, and bystander activity. Pharmacokinetic analysis showed dose-proportional PK, with linear biphasic PK &gt;/= 4mg/kg in cynomolgus monkey. Safety studies in cynomolgus monkey treated with 4, 8 or 12 mg/kg demonstrated that findings were non-adverse, monitorable and manageable. All doses were tolerated with few clinical observations and minimal to mild clinical pathology changes. Target organs were skin, bone marrow, lung and eye. The HNSTD (highest non-severely toxic dose) was 12 mg/kg. This dose enabled a starting dose of 0.6 mg/kg for phase 1 testing. Conclusions: DHES0815A is a HER2-directed ADC comprised of a domain I binding antibody linked to a reduced potency PBD dimer, PBD-MA, via a reducible disulfide linker. The antibody does not interfere with trastuzumab or pertuzumab binding, allowing combination with existing HER2 therapies. The reduced potency payload allows dosing in the linear PK range, supporting our hypothesis. DHES0815A demonstrated dose-dependent anti-tumor efficacy in multiple HER2+ breast and gastric cancer models, and showed efficacy in HER2-low models, where T-DM1 was inactive. Enhanced anti-tumor activity was observed combining DHES0815A with T-DM1, trastuzumab/pertuzumab or docetaxel. Studies in cynomolgus monkey demonstrated a safety profile compatible with initiating a phase 1 clinical trial. The phase 1 data will be presented in a separate presentation. Citation Format: Gail Lewis Phillips, Guangmin Li, Jun Guo, Shang-Fan Yu, Genee Lee, Donglu Zhang, Peter Dragovich, Thomas Pillow, Binqing Wei, M. Violet Lee, Ola Saad, Shab Masih, Douglas Leipold, Lisa Crocker, Melissa Schutten. Preclinical development of DHES0815A: A HER2-directed antibody-drug conjugate comprised of a reduced potency PBD dimer linked to a domain I binding HER2 antibody [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-13-33." @default.
• W4220807744 created "2022-04-03" @default.
• W4220807744 creator A5005988952 @default.
• W4220807744 creator A5012042690 @default.
• W4220807744 creator A5030816359 @default.
• W4220807744 creator A5038648623 @default.
• W4220807744 creator A5050813261 @default.
• W4220807744 creator A5051844828 @default.
• W4220807744 creator A5052044457 @default.
• W4220807744 creator A5054082820 @default.
• W4220807744 creator A5055096416 @default.
• W4220807744 creator A5055608551 @default.
• W4220807744 creator A5064125880 @default.
• W4220807744 creator A5066818395 @default.
• W4220807744 creator A5071427177 @default.
• W4220807744 creator A5073515105 @default.
• W4220807744 creator A5075200671 @default.
• W4220807744 date "2022-02-15" @default.
• W4220807744 modified "2023-10-11" @default.
• W4220807744 title "Abstract P2-13-33: Preclinical development of DHES0815A: A HER2-directed antibody-drug conjugate comprised of a reduced potency PBD dimer linked to a domain I binding HER2 antibody" @default.
• W4220807744 doi "https://doi.org/10.1158/1538-7445.sabcs21-p2-13-33" @default.
• W4220807744 hasPublicationYear "2022" @default.
• W4220807744 type Work @default.
• W4220807744 citedByCount "1" @default.
• W4220807744 countsByYear W42208077442022 @default.
• W4220807744 crossrefType "journal-article" @default.
• W4220807744 hasAuthorship W4220807744A5005988952 @default.
• W4220807744 hasAuthorship W4220807744A5012042690 @default.
• W4220807744 hasAuthorship W4220807744A5030816359 @default.
• W4220807744 hasAuthorship W4220807744A5038648623 @default.
• W4220807744 hasAuthorship W4220807744A5050813261 @default.
• W4220807744 hasAuthorship W4220807744A5051844828 @default.
• W4220807744 hasAuthorship W4220807744A5052044457 @default.
• W4220807744 hasAuthorship W4220807744A5054082820 @default.
• W4220807744 hasAuthorship W4220807744A5055096416 @default.
• W4220807744 hasAuthorship W4220807744A5055608551 @default.
• W4220807744 hasAuthorship W4220807744A5064125880 @default.
• W4220807744 hasAuthorship W4220807744A5066818395 @default.
• W4220807744 hasAuthorship W4220807744A5071427177 @default.
• W4220807744 hasAuthorship W4220807744A5073515105 @default.
• W4220807744 hasAuthorship W4220807744A5075200671 @default.
• W4220807744 hasConcept C111919701 @default.
• W4220807744 hasConcept C134306372 @default.
• W4220807744 hasConcept C150903083 @default.
• W4220807744 hasConcept C159654299 @default.
• W4220807744 hasConcept C185592680 @default.
• W4220807744 hasConcept C197336794 @default.
• W4220807744 hasConcept C202751555 @default.
• W4220807744 hasConcept C203014093 @default.
• W4220807744 hasConcept C207001950 @default.
• W4220807744 hasConcept C2777325958 @default.
• W4220807744 hasConcept C2780557392 @default.
• W4220807744 hasConcept C33923547 @default.
• W4220807744 hasConcept C41008148 @default.
• W4220807744 hasConcept C542903549 @default.
• W4220807744 hasConcept C55493867 @default.
• W4220807744 hasConcept C57992300 @default.
• W4220807744 hasConcept C71924100 @default.
• W4220807744 hasConcept C86803240 @default.
• W4220807744 hasConcept C98274493 @default.
• W4220807744 hasConceptScore W4220807744C111919701 @default.
• W4220807744 hasConceptScore W4220807744C134306372 @default.
• W4220807744 hasConceptScore W4220807744C150903083 @default.
• W4220807744 hasConceptScore W4220807744C159654299 @default.
• W4220807744 hasConceptScore W4220807744C185592680 @default.
• W4220807744 hasConceptScore W4220807744C197336794 @default.
• W4220807744 hasConceptScore W4220807744C202751555 @default.
• W4220807744 hasConceptScore W4220807744C203014093 @default.
• W4220807744 hasConceptScore W4220807744C207001950 @default.
• W4220807744 hasConceptScore W4220807744C2777325958 @default.
• W4220807744 hasConceptScore W4220807744C2780557392 @default.
• W4220807744 hasConceptScore W4220807744C33923547 @default.
• W4220807744 hasConceptScore W4220807744C41008148 @default.
• W4220807744 hasConceptScore W4220807744C542903549 @default.
• W4220807744 hasConceptScore W4220807744C55493867 @default.
• W4220807744 hasConceptScore W4220807744C57992300 @default.
• W4220807744 hasConceptScore W4220807744C71924100 @default.
• W4220807744 hasConceptScore W4220807744C86803240 @default.
• W4220807744 hasConceptScore W4220807744C98274493 @default.
• W4220807744 hasIssue "4_Supplement" @default.
• W4220807744 hasLocation W42208077441 @default.
• W4220807744 hasOpenAccess W4220807744 @default.
• W4220807744 hasPrimaryLocation W42208077441 @default.
• W4220807744 hasRelatedWork W2062789585 @default.
• W4220807744 hasRelatedWork W2893386726 @default.
• W4220807744 hasRelatedWork W2922195937 @default.
• W4220807744 hasRelatedWork W3092771134 @default.
• W4220807744 hasRelatedWork W3198555777 @default.
• W4220807744 hasRelatedWork W4214766446 @default.
• W4220807744 hasRelatedWork W4313278730 @default.
• W4220807744 hasRelatedWork W4362476709 @default.
• W4220807744 hasRelatedWork W4365135407 @default.
• W4220807744 hasRelatedWork W4366318369 @default.
• W4220807744 hasVolume "82" @default.
• W4220807744 isParatext "false" @default.
• W4220807744 isRetracted "false" @default.
• W4220807744 workType "article" @default.